Cornelis Kluft1, Yvette Zimmerman2, Marie Mawet3, Christine Klipping4, Ingrid J M Duijkers5, Jacoline Neuteboom6, Jean-Michel Foidart7, Herjan Coelingh Bennink8. 1. Good Biomarker Sciences, Zernikedreef 8, 2333CL, Leiden, the Netherlands. Electronic address: kluft@kluft.in. 2. Pantarhei Bioscience, P.O. Box 464, 3700, AL, Zeist, the Netherlands. Electronic address: yz@pantarheioncology.nl. 3. Estetra SPRL, Rue Saint Exupery, 4460 Grace-Hollogne, Belgium. Electronic address: mmawet@mithra.com. 4. Dinox BV, Hanzeplein 1, 9713GZ, Groningen, the Netherlands. Electronic address: c.klipping@dinox.umcg.nl. 5. Dinox BV, Hanzeplein 1, 9713GZ, Groningen, the Netherlands. Electronic address: i.j.m.duijkers@dinox.umcg.nl. 6. Good Biomarker Sciences, Zernikedreef 8, 2333CL, Leiden, the Netherlands. Electronic address: neuteboom@gbsleiden.nl. 7. Estetra SPRL, Rue Saint Exupery, 4460 Grace-Hollogne, Belgium. Electronic address: jfevaconsulting@gmail.com. 8. Pantarhei Bioscience, P.O. Box 464, 3700, AL, Zeist, the Netherlands. Electronic address: hcb@pantarheibio.com.
Abstract
OBJECTIVE: The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone (DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG), angiotensinogen and 12 hemostasis markers. STUDY DESIGN: Combinations of 3 mg DRSP with 5 or 10 mg E4 were compared with YAZ® (20 mcg ethinyl estradiol and 3 mg DRSP; EE/DRSP) in parallel groups of 15-18 healthy young women. Main outcome was the relative change from pretreatment to the end (day 24±1) of the third treatment cycle. RESULTS: All E4 combinations showed low estrogen impact compared to EE/DRSP. Effects on SHBG and angiotensinogen of 10 mg E4 combined with DRSP were 15%-20% that of EE/DRSP. Both E4/DRSP combinations reduced D-dimer level and the 5 mg E4/DRSP combination also decreased fragment 1+2. CONCLUSIONS: The reduction in coagulation markers suggests an anticoagulant effect from DRSP. The indications of a low thrombosis risk for E4 preparations should be validated in larger studies. IMPLICATION STATEMENT.
OBJECTIVE: The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone (DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG), angiotensinogen and 12 hemostasis markers. STUDY DESIGN: Combinations of 3 mg DRSP with 5 or 10 mg E4 were compared with YAZ® (20 mcg ethinyl estradiol and 3 mg DRSP; EE/DRSP) in parallel groups of 15-18 healthy young women. Main outcome was the relative change from pretreatment to the end (day 24±1) of the third treatment cycle. RESULTS: All E4 combinations showed low estrogen impact compared to EE/DRSP. Effects on SHBG and angiotensinogen of 10 mg E4 combined with DRSP were 15%-20% that of EE/DRSP. Both E4/DRSP combinations reduced D-dimer level and the 5 mg E4/DRSP combination also decreased fragment 1+2. CONCLUSIONS: The reduction in coagulation markers suggests an anticoagulant effect from DRSP. The indications of a low thrombosis risk for E4 preparations should be validated in larger studies. IMPLICATION STATEMENT.
Authors: Herjan J T Coelingh Bennink; Jeroen A van Moorselaar; E David Crawford; Erik P M Roos; Diederik M Somford; Ton A Roeleveld; Tjard D de Haan; Harm H E van Melick; Yacov Reisman; Yvette Zimmerman; Gonnie van Osta; Jan Krijgh; Neal D Shore; Fred Saad; Andrew V Schally; Frans M J Debruyne Journal: Eur Urol Open Sci Date: 2021-05-06
Authors: K Gemzell-Danielsson; D Apter; J Zatik; S Weyers; T Piltonen; L Suturina; I Apolikhina; M Jost; M D Creinin; J-M Foidart Journal: BJOG Date: 2021-08-09 Impact factor: 7.331